Navigation Links
Anthera Completes Enrollment and Dosing of Varespladib Cardiovascular Trial
Date:1/12/2009

HAYWARD, Calif., Jan. 12 /PRNewswire/ -- Anthera Pharmaceuticals, Inc., a privately held biopharmaceutical company developing anti-inflammatory drugs, announced today that it has completed enrollment in its 500 patient FRANCIS (Fewer Recurrent Acute coronary events with Near-term Cardiovascular Inflammation Suppression) clinical trial designed to examine the impact of varespladib (A-002) when administered to patients within 96 hours of an Acute Coronary Syndrome (ACS) event.

"We are pleased with the continued progress of our varespladib cardiovascular program targeting secretory phospholipase A2," said Paul Truex, President and Chief Executive Officer of Anthera Pharmaceuticals, Inc. "The multiple therapeutic impact of varespladib's mechanism of action provides us with a unique opportunity to develop a first-in-class product targeting a life-threatening coronary event for which there are limited therapeutic options."

"With the varespladib trial fully enrolled, we look forward to reporting the biomarker results and event trends later this year," said Colin Hislop, M.D., Senior Vice President of Clinical Development at Anthera Pharmaceuticals, Inc. "Based upon the positive results from varespladib's two previous Phase II clinical trials that demonstrated lipid-lowering and anti- inflammatory benefits, we look forward to examining the impact of varespladib on the hyper-inflammatory state presented by ACS patients."

Anthera's FRANCIS trial is based upon direct feedback from FDA via the Special Protocol Assessment procedure. The trial is designed to assess the impact of oral varespladib on known biological markers of cardiovascular risk. Anthera plans to enroll between 500-700 patients that will be treated for up to six months. The study is being conducted at sites across North America and Europe. The FRANCIS trial is expected to provide further insight into the prevention of secondary Major
'/>"/>

SOURCE Anthera Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. European EMEA Acceptance of Marketing Authorization Application Filing for SNT-MC17 in Friedreichs Ataxia by Santhera
2. Anthera Pharmaceuticals Forms Scientific Advisory Board
3. Anthera Presents Data on Varespladib at ATVB Meeting
4. Anthera Pharmaceuticals Completes $19 Million Financing; Appoints Christopher S. Henney as Chairman
5. Antheras Varespladib Demonstrates Significant Anti-Inflammatory Effect and LDL Reduction in Patients With Coronary Heart Disease
6. H2Diesel Completes 3 Million Gallon Per Year Pilot Facility
7. AEterna Zentaris completes management team with the appointment of Chief Medical Officer
8. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
9. Carrington Completes $8 Million Financing
10. Proteon Therapeutics Completes $12 Million Financing and Hires CFO
11. New Brunswick Scientific Completes Merger Transaction with Eppendorf
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/11/2014)... Frederick, MD (PRWEB) September 12, 2014 ... systems (LIMS), radio-frequency identification (RFID) solutions and sample ... version 5.1. , RURO completed work on the ... late August and it has already seen mass ... recent major release of version 5.0 brought an ...
(Date:9/11/2014)... team of Berkeley Lab researchers believes it has ... of single atomic layers of transition metal dichalcogenide ... promise for nanoelectronic and photonic applications. , ... of tungsten disulfide, one of the most promising ... existence of excitonic dark states energy states ...
(Date:9/11/2014)... surface of graphene, a one atom thick sheet of ... graphene oxide; a form of graphene that could have ... industries. Applied as paint, it could provide an ultra-strong, ... , Graphene oxide solutions can be used to ... even conventional bricks. After a simple chemical treatment, the ...
(Date:9/11/2014)... Sept. 11, 2014 XBiotech announced today it ... machine that the Company says will be used to ... system is designed to fill, stopper and crimp vials, ... Additionally, the unit is said to contain an in-line ... provide a high level of quality compared to less ...
Breaking Biology Technology:Limfinity® Version 5.1 Available 2Excitonic dark states shed light on TMDC atomic layers 2Excitonic dark states shed light on TMDC atomic layers 3Graphene paints a corrosion-free future 2
... Press Ganey Associates, Inc. has announced its elite class ... the first-ever Summit and Top Improver awards for clinical ... Medical Centers. Press Ganey, the health ... more than 10,000 health care organizations worldwide to create ...
... Calif., Nov. 15, 2011 Quest Diagnostics Incorporated (NYSE: ... diagnostic testing, information and services, today announced that its ... Cytomegalovirus (CMV) molecular test kit on the 3M™ Integrated ... The test is designed to enable hospital labs to ...
... AURORA, Colo., Nov. 15, 2011 In a strategic ... Redevelopment Authority (FRA) has completed a regimen of planning ... allocation of resources going forward. The announcement is made ... "Our first tactic in refocus involves augmenting our board ...
Cached Biology Technology:Nation's Best Health Care Organizations for Patient Satisfaction, Core Measures Honored by Press Ganey 2Nation's Best Health Care Organizations for Patient Satisfaction, Core Measures Honored by Press Ganey 3Quest Diagnostics CE Marks Simplexa™ Test for Cytomegalovirus for Sale in Europe 2Quest Diagnostics CE Marks Simplexa™ Test for Cytomegalovirus for Sale in Europe 3Fitzsimons Redevelopment Authority Rolls Out First Phase of Strategic Refocus With Appointment of Four Key Leaders in The Bioscience Industry to Its Board of Directors 2
(Date:9/11/2014)... professor of mechanical engineering at Worcester Polytechnic ... university,s Integrative Materials Design Center (iMdc), has ... National Science Foundation (NSF) to support the ... metal-ceramic composites, which can be used to ... while significantly increasing their performance. , The ...
(Date:9/11/2014)... 11, 2014 UT Southwestern Medical Center, 2M Companies, ... research and drug development for neurodegenerative disorders caused by ... week, UT Southwestern researchers published a new paper about ... has been shown to help in various animal models ... to Dallas-based 2M Companies. 2M and Calico have now ...
(Date:9/11/2014)... In a study that sheds light on the ... of South America, LSU Museum of Natural Science Director ... Biological Sciences, Robb Brumfield, and an international team of ... published a paper this week challenging the view that ... formed is directly linked to geological and climatic ...
Breaking Biology News(10 mins):NSF funds new method for making materials that can make lighter, more efficient vehicles 2NSF funds new method for making materials that can make lighter, more efficient vehicles 3Calico enters into exclusive collaboration with 2M to develop UTSW technology 2Calico enters into exclusive collaboration with 2M to develop UTSW technology 3LSU scientists lead research on speciation in the tropics 2
... Ivaska (University of Turku and VTT Technical Research Centre of ... National Institute for Health and Welfare) have discovered that the ... a leading journal, the study concludes that SHARPIN regulates the ... prostate cancer cells. It is likely that the discovery will ...
... risk of extinction is a complicated task, especially for species ... University of Georgia and Tulane University have developed a mathematical ... appears in the early online edition of the Royal Society ... for a lot of species, we don,t know very much ...
... might lead to the development of better intervention methods, according ... published in the journal Substance Use & Misuse ... prompted college students to recall their smoking experience, and that ... and on weekends. "Students are using social events ...
Cached Biology News:New model more accurately describes migratory animals' extinction risk 2Research reveals when and why students smoke in effort to help them quit 2
... Zyagen tissue microarrays are derived from ... to rigorous quality control procedures to ensure ... are manually assembled in one block, sectioned ... mounted on coated slides. Sections are large ...
... Zyagen tissue microarrays are derived from frozen ... rigorous quality control procedures to ensure the ... manually assembled in one block, sectioned at ... coated slides. Sections are large (3-5mm in ...
... The DNA Engine Opticon real-time PCR detection ... for fluorescence excitation (450-495 nm) and a ... The Opticon system is built on an ... a thermal gradient feature. This item includes ...
... for Optimal Microdissection , CapSure HS and ... and rapid extraction of populations of pure ... with Laser Capture Microdissection., Ensure the ... Analysis , All CapSure LCM Caps have ...
Biology Products: